This pathway is one of the mechanisms through which GLP-1R agonists are thought to provide neuroprotection in multiple in vitro and animal models of Parkinson’s and Alzheimer’s neurodegeneration (Erbil et al., 2019). This evidence concerns the gene GLP1R and Parkinsonism.